1. Positive SARS-CoV-2 test results within the last 72 hours (obtained using either nasopharyngeal, saliva, or throat samples, by either reverse transcriptase-polymerase chain reaction [RT-PCR] or antigen technic). 2. An onset of any clinical signs and symptoms suggestive of COVID-19 disease (eg, headaches, sore throat, myalgia, fatigue, fever >38°C, nasal congestion, rhinorrhoea, sneezing, cough, anosmia-or-ageusia), with at least one clinical signs and symptoms starting within the last 72 hours. 3. Non-hospitalised patient. 4. Adult male or female patients ≥50 years of age. 5. Willing to comply with all study procedures. 6. Able to understand and willing to provide informed consent. 7. For females only: At the time of enrolment, negative beta-human chorionic gonadotropin pregnancy test (urine) for women of childbearing potential. 8. Patient covered by health insurance during the study period.

1. Positive SARS-CoV-2 test results within the last 72 hours (obtained using either nasopharyngeal, saliva, or throat samples, by either reverse transcriptase-polymerase chain reaction [RT-PCR] or antigen technic). 2. An onset of any clinical signs and symptoms suggestive of COVID-19 disease (eg, headaches, sore throat, myalgia, fatigue, fever >38°C, nasal congestion, rhinorrhoea, sneezing, cough, anosmia-or-ageusia), with at least one clinical signs and symptoms starting within the last 72 hours. 3. Non-hospitalised patient. 4. Adult male or female patients ≥50 years of age. 5. Willing to comply with all study procedures. 6. Able to understand and willing to provide informed consent. 7. For females only: At the time of enrolment, negative beta-human chorionic gonadotropin pregnancy test (urine) for women of childbearing potential. 8. Patient covered by health insurance during the study period.